SPTX Seaport Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2042347 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets4.8%
Debt / equity0.00x
Current ratio17.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $23.89M | $24.62M | $21.43M | $20.45M | $13.41M | $10.53M |
| SG&A expense | $6.45M | $41.19M | $6.11M | $4.99M | $5.06M | $5.65M |
| Operating income | -$30.34M | -$65.81M | -$27.54M | -$25.44M | -$18.47M | -$16.18M |
| Pretax income | -$26.27M | -$62.35M | -$24.89M | -$22.45M | -$14.94M | -$13.09M |
| Income tax | $127,000 | $251,000 | $519,000 | $95,000 | $134,000 | $31,000 |
| Net income | -$26.39M | -$62.60M | -$25.41M | -$22.54M | -$15.08M | -$13.12M |
| EBITDA | -$30.32M | -$65.78M | -$27.52M | -$25.39M | -$18.43M | -$16.15M |
| EPS (basic) | -0.49 | -1.78 | -10.34 | -9.43 | -6.40 | -5.65 |
| EPS (diluted) | -0.49 | -1.78 | -10.34 | -9.43 | -6.40 | -5.65 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | — | — | — |
| Weighted avg. shares (diluted) | 53.53M | 35.24M | 2.46M | 2.39M | 2.36M | 2.32M |
| Balance sheet | ||||||
| Cash & equivalents | $61.55M | $64.22M | $52.91M | — | — | — |
| Short-term investments | $228.88M | $209.09M | $129.70M | — | — | — |
| Current assets | $299.06M | $282.18M | $188.34M | — | — | — |
| PP&E, net | $333,000 | $360,000 | $386,000 | — | — | — |
| Total assets | $417.62M | $441.68M | $227.67M | — | — | — |
| Current liabilities | $17.11M | $15.67M | $14.22M | — | — | — |
| Total liabilities | $20.17M | $19.08M | $17.97M | — | — | — |
| Shareholders' equity | $397.45M | $422.60M | -$115.62M | -$70.21M | -$49.55M | -$36.16M |
| Shares outstanding | 53.53M | 53.53M | 2.60M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$22.68M | -$26.14M | -$20.17M | -$15.77M | -$15.32M | -$20.20M |
| Capital expenditure | $0 | $0 | $0 | $8,000 | $269,000 | $54,000 |
| Free cash flow | -$22.68M | -$26.14M | -$20.17M | -$15.77M | -$15.59M | -$20.26M |
| Investing cash flow | $20.11M | -$203.50M | $27.85M | $15.09M | -$1.44M | -$225.55M |
| Financing cash flow | -$97,000 | $240.93M | -$783,000 | $1,000 | $0 | $0 |
| Depreciation & amortization | $27,000 | $26,000 | $26,000 | $54,000 | $41,000 | $36,000 |
| Stock-based compensation | $2.45M | $36.86M | $2.57M | $1.78M | $1.76M | $1.62M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.